Subretinal Visual Implant Alpha IMS - Clinical trial interim report

Katarina Stingl, Karl Ulrich Bartz-Schmidt, Dorothea Besch, Caroline K. Chee, Charles L. Cottriall, Florian Gekeler, Markus Groppe, Timothy L. Jackson, Robert E. MacLaren, Assen Koitschev, Akos Kusnyerik, James Neffendorf, J. Németh, Mohamed Adheem Naser Naeem, Tobias Peters, James D. Ramsden, Helmut Sachs, Andrew Simpson, Mandeep S. Singh, Barbara WilhelmDavid Wong, Eberhart Zrenner

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

A subretinal visual implant (Alpha IMS, Retina Implant AG, Reutlingen, Germany) was implanted in 29 blind participants with outer retinal degeneration in an international multicenter clinical trial. Primary efficacy endpoints of the study protocol were a significant improvement of activities of daily living and mobility to be assessed by activities of daily living tasks, recognition tasks, mobility, or a combination thereof. Secondary efficacy endpoints were a significant improvement of visual acuity/light perception and/or object recognition (clinicaltrials.gov, NCT01024803).During up to 12. months observation time twenty-one participants (72%) reached the primary endpoints, of which thirteen participants (45%) reported restoration of visual function which they use in daily life. Additionally, detection, localization, and identification of objects were significantly better with the implant power switched on in the first 3 months. Twenty-five participants (86%) reached the secondary endpoints. Measurable grating acuity was up to 3.3 cycles per degree, visual acuities using standardized Landolt C-rings were 20/2000, 20/2000, 20/606 and 20/546. Maximal correct motion perception ranged from 3 to 35 degrees per second. These results show that subretinal implants can restore very-low-vision or low vision in blind (light perception or less) patients with end-stage hereditary retinal degenerations.

Original languageEnglish
Pages (from-to)149-160
Number of pages12
JournalVision Research
Volume111
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Low Vision
Retinal Degeneration
Activities of Daily Living
Visual Acuity
Clinical Trials
Motion Perception
Light
Multicenter Studies
Germany
Retina
Observation
Recognition (Psychology)
Power (Psychology)

Keywords

  • Artificial vision
  • Hereditary retinal diseases
  • Neuroprosthetics
  • Photoreceptor degeneration
  • Retinitis pigmentosa
  • Subretinal Implant Alpha IMS

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Stingl, K., Bartz-Schmidt, K. U., Besch, D., Chee, C. K., Cottriall, C. L., Gekeler, F., ... Zrenner, E. (2015). Subretinal Visual Implant Alpha IMS - Clinical trial interim report. Vision Research, 111, 149-160. https://doi.org/10.1016/j.visres.2015.03.001

Subretinal Visual Implant Alpha IMS - Clinical trial interim report. / Stingl, Katarina; Bartz-Schmidt, Karl Ulrich; Besch, Dorothea; Chee, Caroline K.; Cottriall, Charles L.; Gekeler, Florian; Groppe, Markus; Jackson, Timothy L.; MacLaren, Robert E.; Koitschev, Assen; Kusnyerik, Akos; Neffendorf, James; Németh, J.; Naeem, Mohamed Adheem Naser; Peters, Tobias; Ramsden, James D.; Sachs, Helmut; Simpson, Andrew; Singh, Mandeep S.; Wilhelm, Barbara; Wong, David; Zrenner, Eberhart.

In: Vision Research, Vol. 111, 01.06.2015, p. 149-160.

Research output: Contribution to journalArticle

Stingl, K, Bartz-Schmidt, KU, Besch, D, Chee, CK, Cottriall, CL, Gekeler, F, Groppe, M, Jackson, TL, MacLaren, RE, Koitschev, A, Kusnyerik, A, Neffendorf, J, Németh, J, Naeem, MAN, Peters, T, Ramsden, JD, Sachs, H, Simpson, A, Singh, MS, Wilhelm, B, Wong, D & Zrenner, E 2015, 'Subretinal Visual Implant Alpha IMS - Clinical trial interim report', Vision Research, vol. 111, pp. 149-160. https://doi.org/10.1016/j.visres.2015.03.001
Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F et al. Subretinal Visual Implant Alpha IMS - Clinical trial interim report. Vision Research. 2015 Jun 1;111:149-160. https://doi.org/10.1016/j.visres.2015.03.001
Stingl, Katarina ; Bartz-Schmidt, Karl Ulrich ; Besch, Dorothea ; Chee, Caroline K. ; Cottriall, Charles L. ; Gekeler, Florian ; Groppe, Markus ; Jackson, Timothy L. ; MacLaren, Robert E. ; Koitschev, Assen ; Kusnyerik, Akos ; Neffendorf, James ; Németh, J. ; Naeem, Mohamed Adheem Naser ; Peters, Tobias ; Ramsden, James D. ; Sachs, Helmut ; Simpson, Andrew ; Singh, Mandeep S. ; Wilhelm, Barbara ; Wong, David ; Zrenner, Eberhart. / Subretinal Visual Implant Alpha IMS - Clinical trial interim report. In: Vision Research. 2015 ; Vol. 111. pp. 149-160.
@article{eafd1c0f30df45da8a41bfdacde53726,
title = "Subretinal Visual Implant Alpha IMS - Clinical trial interim report",
abstract = "A subretinal visual implant (Alpha IMS, Retina Implant AG, Reutlingen, Germany) was implanted in 29 blind participants with outer retinal degeneration in an international multicenter clinical trial. Primary efficacy endpoints of the study protocol were a significant improvement of activities of daily living and mobility to be assessed by activities of daily living tasks, recognition tasks, mobility, or a combination thereof. Secondary efficacy endpoints were a significant improvement of visual acuity/light perception and/or object recognition (clinicaltrials.gov, NCT01024803).During up to 12. months observation time twenty-one participants (72{\%}) reached the primary endpoints, of which thirteen participants (45{\%}) reported restoration of visual function which they use in daily life. Additionally, detection, localization, and identification of objects were significantly better with the implant power switched on in the first 3 months. Twenty-five participants (86{\%}) reached the secondary endpoints. Measurable grating acuity was up to 3.3 cycles per degree, visual acuities using standardized Landolt C-rings were 20/2000, 20/2000, 20/606 and 20/546. Maximal correct motion perception ranged from 3 to 35 degrees per second. These results show that subretinal implants can restore very-low-vision or low vision in blind (light perception or less) patients with end-stage hereditary retinal degenerations.",
keywords = "Artificial vision, Hereditary retinal diseases, Neuroprosthetics, Photoreceptor degeneration, Retinitis pigmentosa, Subretinal Implant Alpha IMS",
author = "Katarina Stingl and Bartz-Schmidt, {Karl Ulrich} and Dorothea Besch and Chee, {Caroline K.} and Cottriall, {Charles L.} and Florian Gekeler and Markus Groppe and Jackson, {Timothy L.} and MacLaren, {Robert E.} and Assen Koitschev and Akos Kusnyerik and James Neffendorf and J. N{\'e}meth and Naeem, {Mohamed Adheem Naser} and Tobias Peters and Ramsden, {James D.} and Helmut Sachs and Andrew Simpson and Singh, {Mandeep S.} and Barbara Wilhelm and David Wong and Eberhart Zrenner",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.visres.2015.03.001",
language = "English",
volume = "111",
pages = "149--160",
journal = "Vision Research",
issn = "0042-6989",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Subretinal Visual Implant Alpha IMS - Clinical trial interim report

AU - Stingl, Katarina

AU - Bartz-Schmidt, Karl Ulrich

AU - Besch, Dorothea

AU - Chee, Caroline K.

AU - Cottriall, Charles L.

AU - Gekeler, Florian

AU - Groppe, Markus

AU - Jackson, Timothy L.

AU - MacLaren, Robert E.

AU - Koitschev, Assen

AU - Kusnyerik, Akos

AU - Neffendorf, James

AU - Németh, J.

AU - Naeem, Mohamed Adheem Naser

AU - Peters, Tobias

AU - Ramsden, James D.

AU - Sachs, Helmut

AU - Simpson, Andrew

AU - Singh, Mandeep S.

AU - Wilhelm, Barbara

AU - Wong, David

AU - Zrenner, Eberhart

PY - 2015/6/1

Y1 - 2015/6/1

N2 - A subretinal visual implant (Alpha IMS, Retina Implant AG, Reutlingen, Germany) was implanted in 29 blind participants with outer retinal degeneration in an international multicenter clinical trial. Primary efficacy endpoints of the study protocol were a significant improvement of activities of daily living and mobility to be assessed by activities of daily living tasks, recognition tasks, mobility, or a combination thereof. Secondary efficacy endpoints were a significant improvement of visual acuity/light perception and/or object recognition (clinicaltrials.gov, NCT01024803).During up to 12. months observation time twenty-one participants (72%) reached the primary endpoints, of which thirteen participants (45%) reported restoration of visual function which they use in daily life. Additionally, detection, localization, and identification of objects were significantly better with the implant power switched on in the first 3 months. Twenty-five participants (86%) reached the secondary endpoints. Measurable grating acuity was up to 3.3 cycles per degree, visual acuities using standardized Landolt C-rings were 20/2000, 20/2000, 20/606 and 20/546. Maximal correct motion perception ranged from 3 to 35 degrees per second. These results show that subretinal implants can restore very-low-vision or low vision in blind (light perception or less) patients with end-stage hereditary retinal degenerations.

AB - A subretinal visual implant (Alpha IMS, Retina Implant AG, Reutlingen, Germany) was implanted in 29 blind participants with outer retinal degeneration in an international multicenter clinical trial. Primary efficacy endpoints of the study protocol were a significant improvement of activities of daily living and mobility to be assessed by activities of daily living tasks, recognition tasks, mobility, or a combination thereof. Secondary efficacy endpoints were a significant improvement of visual acuity/light perception and/or object recognition (clinicaltrials.gov, NCT01024803).During up to 12. months observation time twenty-one participants (72%) reached the primary endpoints, of which thirteen participants (45%) reported restoration of visual function which they use in daily life. Additionally, detection, localization, and identification of objects were significantly better with the implant power switched on in the first 3 months. Twenty-five participants (86%) reached the secondary endpoints. Measurable grating acuity was up to 3.3 cycles per degree, visual acuities using standardized Landolt C-rings were 20/2000, 20/2000, 20/606 and 20/546. Maximal correct motion perception ranged from 3 to 35 degrees per second. These results show that subretinal implants can restore very-low-vision or low vision in blind (light perception or less) patients with end-stage hereditary retinal degenerations.

KW - Artificial vision

KW - Hereditary retinal diseases

KW - Neuroprosthetics

KW - Photoreceptor degeneration

KW - Retinitis pigmentosa

KW - Subretinal Implant Alpha IMS

UR - http://www.scopus.com/inward/record.url?scp=84941315108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941315108&partnerID=8YFLogxK

U2 - 10.1016/j.visres.2015.03.001

DO - 10.1016/j.visres.2015.03.001

M3 - Article

C2 - 25812924

AN - SCOPUS:84941315108

VL - 111

SP - 149

EP - 160

JO - Vision Research

JF - Vision Research

SN - 0042-6989

ER -